Insider Trading Alert - TTEC, LGND And AMWD Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, June 11, 2015, 92 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $332.85 to $17,302,509.00.

Highlighted Stocks Traded by Insiders:

TeleTech Holdings (TTEC) - FREE Research Report

Deghetto Martin F, who is Evp, Cms at TeleTech Holdings, sold 10,000 shares at $26.00 on June 11, 2015. Following this transaction, the Evp, Cms owned 102,437 shares meaning that the stake was reduced by 8.89% with the 10,000-share transaction.

The shares most recently traded at $26.25, up $0.25, or 0.95% since the insider transaction. Historical insider transactions for TeleTech Holdings go as follows:

  • 4-Week # shares sold: 1,000
  • 12-Week # shares sold: 1,000
  • 24-Week # shares sold: 1,000

The average volume for TeleTech Holdings has been 79,300 shares per day over the past 30 days. TeleTech Holdings has a market cap of $1.3 billion and is part of the services sector and diversified services industry. Shares are up 11.02% year-to-date as of the close of trading on Thursday.

TeleTech Holdings, Inc. provides customer engagement management solutions in the United States, the Philippines, Latin America, Europe, the Middle East, Africa, the Asia Pacific, and Canada. The stock currently has a dividend yield of 1.37%. The company has a P/E ratio of 18.5. Currently, there are 3 analysts who rate TeleTech Holdings a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on TTEC - FREE

TheStreet Quant Ratings rates TeleTech Holdings as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels and notable return on equity. We feel its strengths outweigh the fact that the company shows low profit margins. Get the full TeleTech Holdings Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Ligand Pharmaceuticals (LGND) - FREE Research Report

Higgins John L, who is Chief Executive Officer at Ligand Pharmaceuticals, sold 10,000 shares at $92.88 on June 11, 2015. Following this transaction, the Chief Executive Officer owned 126,044 shares meaning that the stake was reduced by 7.35% with the 10,000-share transaction.

The shares most recently traded at $93.68, up $0.80, or 0.85% since the insider transaction. Historical insider transactions for Ligand Pharmaceuticals go as follows:

  • 4-Week # shares bought: 275
  • 4-Week # shares sold: 4,591
  • 12-Week # shares bought: 275
  • 12-Week # shares sold: 4,591
  • 24-Week # shares bought: 275
  • 24-Week # shares sold: 11,636

The average volume for Ligand Pharmaceuticals has been 422,600 shares per day over the past 30 days. Ligand Pharmaceuticals has a market cap of $1.8 billion and is part of the health care sector and drugs industry. Shares are up 76.96% year-to-date as of the close of trading on Thursday.

Ligand Pharmaceuticals Incorporated operates as a biotechnology company in the United States. The company has a P/E ratio of 186.4. Currently, there are 3 analysts who rate Ligand Pharmaceuticals a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on LGND - FREE

TheStreet Quant Ratings rates Ligand Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its notable return on equity, good cash flow from operations, expanding profit margins and solid stock price performance. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full Ligand Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

American Woodmark (AMWD) - FREE Research Report

Tang Vance W, who is Director at American Woodmark, sold 2,500 shares at $55.95 on June 11, 2015. Following this transaction, the Director owned 12,700 shares meaning that the stake was reduced by 16.45% with the 2,500-share transaction.

The shares most recently traded at $56.63, up $0.68, or 1.2% since the insider transaction. Historical insider transactions for American Woodmark go as follows:

  • 4-Week # shares sold: 23,979
  • 12-Week # shares sold: 47,979
  • 24-Week # shares sold: 107,979

The average volume for American Woodmark has been 138,200 shares per day over the past 30 days. American Woodmark has a market cap of $891.4 million and is part of the consumer goods sector and consumer durables industry. Shares are up 38.55% year-to-date as of the close of trading on Thursday.

American Woodmark Corporation manufactures and distributes kitchen cabinets and vanities for the remodeling and home construction markets in the United States. The company offers framed stock cabinets in approximately 600 various cabinet lines, which include 85 door designs in 19 colors. The company has a P/E ratio of 25.4. Currently, there is 1 analyst who rates American Woodmark a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on AMWD - FREE

TheStreet Quant Ratings rates American Woodmark as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and good cash flow from operations. We feel its strengths outweigh the fact that the company shows low profit margins. Get the full American Woodmark Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

Stocks Tumble as Trump Calls Off North Korea Summit

Stocks Tumble as Trump Calls Off North Korea Summit

Stocks Could Easily Crater Into Memorial Day Weekend

Stocks Could Easily Crater Into Memorial Day Weekend

Video: Here Is How Real Estate Investment Trusts Can Boost Your Portfolio

Video: Here Is How Real Estate Investment Trusts Can Boost Your Portfolio

Celgene Shares Rise on Plans to Increase Stock Buybacks

Celgene Shares Rise on Plans to Increase Stock Buybacks

Global Stocks Slide as Trump's New Trade War Salvo Ignites Fresh Concern

Global Stocks Slide as Trump's New Trade War Salvo Ignites Fresh Concern